Fate Therapeutics Posts Q4 Loss of $0.27, Revenue Drops 26% to $1.37M
Fate Therapeutics reported a Q4 adjusted loss of $0.27 per share, matching consensus and improving from a $0.31 loss year-ago, while revenue fell 26.3% to $1.37 million, missing estimates by 8.7%. Shares have risen 50.6% year-to-date despite the shortfall, with analysts forecasting a Q1 loss of $0.30 on $1.5 million.
1. Q4 Financial Results
Fate Therapeutics reported an adjusted loss of $0.27 per share for Q4, in line with consensus and an improvement from a $0.31 loss in the prior year. Revenue of $1.37 million declined 26.3% year-over-year and missed estimates by 8.7%.
2. Stock Performance
Despite the revenue shortfall, shares have climbed 50.6% year-to-date compared with a 1.5% gain in the S&P 500, driven by four consecutive quarterly EPS beats. This performance underscores investor confidence in the company’s clinical-stage stem cell pipeline.
3. Outlook and Analyst Estimates
Analysts currently project a Q1 loss of $0.30 per share on $1.5 million in revenue, with full-year estimates of a $1.16 loss on $6 million in sales. The biomedical and genetics industry ranks in the top 36% of peer groups, highlighting sector strength.